Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
Gibson, C Michael; Mehran, Roxana; Bode, Christoph; Halperin, Jonathan; Verheugt, Freek W; Wildgoose, Peter; Birmingham, Mary; Ianus, Juliana; Burton, Paul; van Eickels, Martin; Korjian, Serge; Daaboul, Yazan; Lip, Gregory Y H; Cohen, Marc; Husted, Steen; Peterson, Eric D; Fox, Keith A.
N Engl J Med
; 375(25): 2423-2434, 2016 12 22.
Artigo em Inglês | MEDLINE | ID: mdl-27959713
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
The future of P2Y12 receptor antagonists.
Antithrombotic therapy strategies for atrial fibrillation patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis.
Significant Discovery of Tetrahydrothieno[3,2-c]pyridine-2-carboxamide Analogs as Potent P2Y12 Receptor Antagonists.
The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review.
[Experience with Prasugrel in the Treatment of Patients with Acute Coronary Syndrome].
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.